🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "significant breakthrough" in the effort against superbug strains of the bacteria, according to scientists.

A Global Public Health Issue

The sexually transmitted infection are increasing worldwide, with data suggesting in excess of 82 million infections per year. Notably increased rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an important and timely advancement in the face of rising global incidence, the spread of superbugs and the extremely scarce available drugs at this time.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Approval

One new antibiotic, alternatively called a brand name, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts hope that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, was also approved in the same week. This medication, which is also used to treat urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP worked alongside the drug firm Innoviva to see it through.

“This milestone represents a significant shift in the treatment of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Results and Worldwide Availability

According to data published in a prominent scientific publication, the new drug cured the vast majority of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which combines a dual-drug approach. The study enrolled nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the ability to make available and distribute the drug in a wide range of regions with limited resources.

Medical professionals treating patients have voiced hope. Access to a one-pill regimen of this kind is hailed as a "game-changer" for public health efforts. This is viewed as essential to alleviate the strain of the illness for people and to halt the transmission of untreatable gonorrhoea worldwide.